粪便隐血试验阳性接受结肠镜检查者的上消化道内镜检查:系统评价与荟萃分析
该系统评价与荟萃分析纳入21项研究共6993例粪便隐血试验阳性受试者,评估其接受结肠镜和胃镜检查时上消化道病变的患病率。上消化道癌症汇总患病率为0.8%,临床显著病变为30.4%;贫血与上消化道癌症(OR 6.3)和临床显著病变(OR 4.3)相关,而胃肠道症状与上消化道临床显著病变无显著关联(OR 1.3,P=.511)。作者认为需前瞻性数据确定双内镜作为所有粪便隐血阳性者标准诊疗的成本效益。
要点
- 粪便隐血试验阳性者上消化道癌症汇总患病率0.8%,临床显著病变30.4%。
- 贫血与上消化道癌症(OR 6.3)及临床显著病变(OR 4.3)相关。
- 结肠病变与上消化道临床显著病变和癌症均无显著关联。
核心结论
- 粪便隐血试验阳性受试者上消化道癌症和其他临床显著病变患病率可观。
- 贫血而非症状或结肠病理与上消化道病变相关。
- 数据提示粪便隐血阳性者结肠镜检查当日行胃镜较单纯结肠镜多检出约25%的恶性肿瘤,但需前瞻性数据确定双内镜作为所有粪便隐血阳性者标准诊疗的成本效益。
研究设计与样本
- 系统评价与荟萃分析,检索数据库截至2022年3月31日。
- 纳入报告粪便隐血试验阳性受试者接受结肠镜和胃镜检查时上消化道病变的研究。
- 共纳入21项研究,6993例粪便隐血试验阳性受试者。
主要发现
- 上消化道癌症汇总患病率为0.8%(95% CI,0.4-1.6),上消化道临床显著病变为30.4%(95% CI,20.7-42.2)。
- 结肠癌汇总患病率为3.3%(95% CI,1.8-6.0),结肠临床显著病变为31.9%(95% CI,23.9-41.1)。
- 有或无结肠病理的粪便隐血阳性受试者上消化道临床显著病变和癌症患病率无显著差异(OR分别为1.2 [95% CI,0.9-1.6;P=.137]和1.6 [95% CI,0.5-5.5;P=.460])。
- 粪便隐血阳性受试者中贫血与上消化道癌症(OR 6.3;95% CI,1.3-31.5;P=.025)和上消化道临床显著病变(OR 4.3;95% CI,2.2-8.4;P=.0001)相关。
- 胃肠道症状与上消化道临床显著病变无显著关联(OR 1.3;95% CI,0.6-2.8;P=.511)。
临床怎么用
- 作者认为,数据提示粪便隐血试验阳性者在结肠镜检查当日行胃镜较单纯结肠镜多检出约25%的恶性肿瘤。
- 作者指出,需前瞻性数据确定双内镜作为所有粪便隐血试验阳性者标准诊疗的成本效益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The role of gastroscopy to investigate the upper GI (UGI) tract in subjects with a positive fecal occult blood test (FOBT+) result is controversial. We conducted a systematic review and meta-analysis, which aimed to determine the prevalence of UGI lesions in FOBT+ subjects. METHODS: Databases were searched until March 31, 2022 for studies reporting UGI lesions in FOBT+ subjects undergoing colonoscopy and gastroscopy. Pooled prevalence rates of UGI cancers and clinically significant lesions (CSLs; lesions potentially explaining occult blood loss), odds ratio (OR), and 95% confidence intervals (CIs) were calculated. RESULTS: We included 21 studies with 6993 FOBT+ subjects. Pooled prevalence of UGI cancers was .8% (95% CI, .4-1.6) and UGI CSLs was 30.4% (95% CI, 20.7-42.2), and that of colonic cancers and CSLs was 3.3% (95% CI, 1.8-6.0) and 31.9% (95% CI, 23.9-41.1), respectively. There was no significant difference in the prevalence of UGI CSL and UGI cancers in FOBT+ subjects with/without colonic pathology (ORs of 1.2 [95% CI, .9-1.6; P = .137] and 1.6 [95% CI, .5-5.5; P = .460]). Anemia in FOBT+ subjects was associated with UGI cancers (OR, 6.3; 95% CI, 1.3-31.5; P = .025) and UGI CSLs (OR, 4.3; 95% CI, 2.2-8.4; P = .0001). GI symptoms were not associated with UGI CSLs (OR, 1.3; 95% CI, .6-2.8; P = .511). CONCLUSIONS: There is an appreciable prevalence of UGI cancers and other CSLs in FOBT+ subjects. Anemia but not symptoms or colonic pathology are linked to UGI lesions. Although the data suggest that same-day gastroscopy in FOBT+ subjects undergoing colonoscopy yields approximately 25% more malignancies as colonoscopy alone, prospective data are required to determine the cost-efficacy of dual endoscopy as a standard of care for all FOBT+ subjects.
引用
- Shah A, Eqbal A, Moy N, et al. Upper GI endoscopy in subjects with positive fecal occult blood test undergoing colonoscopy: systematic review and meta-analysis. Gastrointest Endosc. 2023. PMID: 36812947. doi:10.1016/j.gie.2023.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。